Wambui Machua, MD
Rheumatology · Atlanta, GANPI 1144541079
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by GSK at 39.6% of the total. 2025 is the largest year on record at $12,165, more than ten times the $882 reported in 2019.
Across 449 payments — averaging $69.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$12K
- AstraZeneca$4K
- Johnson & Johnson$4K
- UCB, Inc.$2K
- AbbVie$2K
- Amgen$2K
- plus $4K from 25 others
Across 129 payments — averaging $13,509 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$916K
- Eli Lilly$313K
- E.r. Squibb & Sons, L.L.C.$139K
- Amgen$107K
- GSK$96K
- Bristol Myers Squibb$67K
- plus $105K from 4 others
What the payments were for
- Consulting fees$13,17042%
- Travel & lodging$5,54018%
- Food & beverage$12,21239%
- Education$2601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 48 | $12,360 |
| AstraZeneca(2 entities) | 28 | $4,408 |
| Johnson & Johnson | 34 | $4,398 |
| UCB, Inc. | 36 | $2,382 |
| AbbVie | 89 | $2,032 |
| Amgen(2 entities) | 74 | $1,684 |
| Novartis | 46 | $945 |
| Pfizer | 27 | $499 |
| Aurinia Pharma U.S., Inc. | 6 | $461 |
| Janssen Scientific Affairs, LLC | 3 | $261 |
| Argenx US, Inc. | 4 | $245 |
| E.r. Squibb & Sons, L.L.C. | 5 | $232 |
| Lilly USA, LLC | 7 | $175 |
| Sanofi | 6 | $154 |
| Sanofi-aventis U.S. LLC | 5 | $116 |
| Biogen | 1 | $112 |
| Bristol Myers Squibb | 3 | $104 |
| Genentech USA, Inc. | 5 | $100 |
| Janssen Research & Development, LLC | 1 | $82 |
| Radius Health, Inc. | 3 | $70 |
| Biocon Biologics Inc | 3 | $58 |
| Boehringer Ingelheim | 2 | $53 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $48 |
| Zyla Life Sciences, Inc. | 3 | $42 |
| Organon | 2 | $37 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Sobi, Inc | 1 | $17 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,182 in reported general payments places this provider in the 85th percentile of 177 rheumatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 26 | $178,479 |
| Enbrel SureclickEtanercept | 24 | $172,832 |
| Mycophenolate Mofetil | 38 | $22,382 |
| RasuvoMethotrexate/Pf | 29 | $15,967 |
| Hydroxychloroquine Sulfate | 190 | $8,312 |
| Leflunomide | 46 | $2,526 |
| MethotrexateMethotrexate Sodium | 90 | $2,017 |
| Prednisone | 79 | $549 |
| Azathioprine | 16 | $418 |
| Allopurinol | 56 | $399 |
| Methylprednisolone | 29 | $335 |
| Sulfasalazine DrSulfasalazine | 15 | $278 |
| Folic Acid | 12 | $98 |
| Meloxicam | 13 | $93 |
| Alendronate Sodium | 12 | $62 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Atlanta
- Gary MyersonAtlanta$1M
- William WilsonAtlanta$344K
- Paul SutejAtlanta$140K
- Sung LimAtlanta$125K
- Arezou KhosroshahiAtlanta$66K
- Kimberley WilsonAtlanta$41K
- John GoldmanAtlanta$33K
- Paula TanasaAtlanta$31K
- Rattandeep SinghAtlanta$20K
- Elizabeth ButlerAtlanta$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.